Phase II Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This trial protocol is designed to evaluate primarily whether the use of sargramostim
(recombinant human GM-CSF), administered five days per week for four consecutive weeks (20
treatment days), will be well tolerated by and safe for use in young adult participants with
Down syndrome.